UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                    FORM 6-K

                    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
                         TO RULE 13a-16 OR 15d-16 UNDER
                       THE SECURITIES EXCHANGE ACT OF 1934

For the month of:  June, 2005

Commission File Number:  000-50393


                                 NEUROCHEM INC.

                         275 Armand-Frappier Boulevard
                                 Laval, Quebec
                                    H7V 4A7


Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40 F.   Form 20-F [ ] Form 40-F [X]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):

                                                                 Yes [ ]  No [X]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):

                                                                 Yes [ ]  No [X]

Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g-3 under the Securities Exchange Act of 1934.

                                                                 Yes [ ]  No [X]

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):


                                   SIGNATURES:

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.



                                        NEUROCHEM INC.
June 30, 2005

                                  By:   /s/    David Skinner
                                        ----------------------------------------
                                        David Skinner
                                        General Counsel and Corporate Secretary







                                                NEUROCHEM INC.
                                                275 Armand-Frappier Blvd.
[NEUROCHEM (LOGO)]                              Laval, Quebec, Canada H7V 4A7
________________________________________________________________________________

FOR FURTHER INFORMATION, PLEASE CONTACT:

Lise Hebert, PhD
Vice President, Corporate Communications                     Tel: (450) 680-4571
Neurochem Inc.                                               Fax: (450) 680-4501
lhebert@neurochem.com



                         NEUROCHEM ANNOUNCES FDA AGREES
                    TO FILE AND REVIEW NDA FOR FIBRILLEX(TM)

ECUBLENS (SWITZERLAND), JUNE 30, 2005 - Neurochem (International) Limited
(Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX; TSX:
NRM), today announced that the U.S. Food and Drug Administration (FDA) has
agreed to file and review a New Drug Application (NDA) for Fibrillex(TM) that
would include the efficacy and safety data from Neurochem's single Phase II/III
trial. Fibrillex(TM) is Neurochem's investigational product candidate for the
treatment of Amyloid A (AA) Amyloidosis. This announcement comes as a result of
a recent meeting with the Cardio-Renal Division of the FDA to discuss the
results of Neurochem's Phase II/III clinical trial. The Agency encouraged
Neurochem to look at and provide additional follow-up data collected from the
open-label extension study as part of its NDA submission.

"AA Amyloidosis is a serious medical condition that frequently leads to organ
dysfunction, subsequent death and for which no specific treatment exists," said
Denis Garceau, PhD, Neurochem's Senior Vice President, Drug Development. "The
filing of our first NDA is a significant event for Neurochem. We are therefore
very pleased that the FDA has agreed to file and review a NDA for Fibrillex(TM),
recognizing its Orphan Drug Status. We look forward to working with the
regulatory agencies and hope to make this potential treatment available to over
40,000 patients in North America and Europe presently diagnosed with the
disease."

As previously announced in December 2004, Neurochem shares an exclusive
collaboration and distribution agreement for Fibrillex(TM) with Centocor, Inc.,
of Malvern, PA (USA).







ABOUT FIBRILLEX(TM)

Fibrillex(TM) is an oral investigational product candidate for the treatment of
AA Amyloidosis through the prevention of amyloid fibril formation. It has
received Orphan Drug Status designation in the United States and Orphan
Medicinal Product designation in Europe.

Fibrillex(TM) also has been accorded "Fast Track Product" designation by the FDA
and has been selected by the Cardio-Renal Drug Product Division of the FDA to be
part of the Continuous Marketing Applications Pilot 2 program aimed at further
accelerating the development of this product candidate. Under this Pilot 2
program, each FDA division is permitted to select only one product candidate.

ABOUT AA AMYLOIDOSIS

AA Amyloidosis is a progressive and fatal condition that occurs in a proportion
of patients with chronic inflammatory diseases, including rheumatoid arthritis,
ankylosing spondylitis, juvenile rheumatoid arthritis, and Crohn's disease. The
disease also occurs in patients suffering from many other conditions ranging
from chronic infections to inherited inflammatory diseases such as Familial
Mediterranean Fever. The most common clinical presentation of AA Amyloidosis is
renal dysfunction. Involvement of the gastrointestinal system is also frequent
and is usually manifested as chronic diarrhea, gastrointestinal bleeding,
abdominal pain and malabsorption. Enlargement of the liver and the spleen may
also occur in some patients. End-stage renal failure is the main cause of death
in 40-60% of cases. The median survival time from diagnosis varies from 2 to 10
years depending on the stage of the disease at the time of diagnosis.

No specific treatment is currently available for this orphan disease. The goal
of existing therapies is limited to the control of the underlying chronic
inflammatory disease.

ABOUT NEUROCHEM

Neurochem is focused on the development and commercialization of innovative
therapeutics for neurological disorders. The Company's pipeline of proprietary,
disease-modifying oral products addresses critical unmet medical needs.
1,3-propanedisulfonate (1,3PDS; Fibrillex(TM)) is designated as an orphan drug
and a Fast Track Product candidate and is also part of an FDA Continuous
Marketing Applications Pilot 2 program. The Phase II/III clinical trial of
Fibrillex(TM) for the treatment of AA Amyloidosis was recently concluded and
results have been released between April and June 2005.
3-amino-1-propanesulfonic acid (3APS; Alzhemed(TM)), for the treatment of
Alzheimer's Disease, is in a Phase III clinical trial and 3APS (Cerebril(TM)),
for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy,
has completed a Phase IIa clinical trial.

TO CONTACT NEUROCHEM

For additional information on Neurochem and its drug development programs,
please call the North American toll-free number 1 877 680-4500 or visit our Web
Site at: www.neurochem.com .
                                      -30-




This news release contains forward-looking statements regarding Fibrillex(TM),
as well as continuing and further development efforts. These statements are
based on the current analysis and expectations of management. Drug development
necessarily involves numerous risks and uncertainties, which could cause actual
results to differ materially from this current analysis and these expectations.
Analysis regarding the results of clinical trials may not provide definitive
results regarding safety, tolerability or therapeutic benefits. There can be no
assurance that a NDA for Fibrillex(TM) would be granted or that any regulator
would ultimately approve it for sale to the public. Risks and uncertainties may
include: failure to demonstrate the safety, tolerability and efficacy of our
product, the expense and uncertainty of obtaining regulatory approval, including
from the FDA, and the possibility of having to conduct additional clinical
trials. Additionally, even if regulatory approval is obtained, therapeutic
products are generally subject to: stringent on-going governmental regulation,
challenges in gaining market acceptance, and competition. Neurochem does not
undertake any obligation to publicly update its forward-looking statements,
whether as a result of new information, future events, or otherwise. Please see
the Annual Information Form for further risk factors that might affect the
Company and its business.